[A21-90] Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 01.10.2021
Commission awarded on 01.07.2021 by the Federal Joint Committee (G-BA).
Treatment of adults with relapsed and refractory multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy
- Patients without prior stem cell therapy: Indication of major added benefit.
- Patients with prior stem cell therapy: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
|Elotuzumab - Benefit assessment according to §35a Social Code Book V